ONO-AE3-208

• Description:

  ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively) . ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer[1][2].

• Product Name Alternative:

  AE 3-208

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/ONO-AE3-208.html

• Concentration:

  10mM

• Purity:

  98.65

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  N#CC1=CC=C (C (NC (C (C2=C3C=CC=CC3=C (F) C=C2) C) =O) =C1) CCCC (O) =O

• Molecular Formula:

  C24H21FN2O3

• Molecular Weight:

  404.43

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Xu S, et al. An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer. Cell Biochem Biophys. 2014 Apr 18.|[2]Ren Y, et al. Prostaglandin E2 mediates connecting tubule glomerular feedback. Hypertension. 2013 Dec;62 (6) :1123-8.|[3]Xu S, et al. Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice. Zhonghua Nan Ke Xue. 2014 Aug;20 (8) :684-9.|[4]Thieme K, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017 Jun 13;7 (1) :3442.|[5]Kenji Kabashima, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109 (7) :883-93.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EP; FP; TXA2/TP

• CAS Number:

  402473-54-5